Presented By: Biomedical Engineering
Biomedical Engineering (BME 500) Seminar Series
"Immunodeficient Rabbit Models: A new platform for biomedical discovery," with Brooke Pallas DVM, DACLAM
Immunodeficient Rabbit Models: A new platform for biomedical discovery
Abstract:
Immunodeficient rodent models have become essential to the advancement of many prominent biomedical fields, including immuno-oncology, regenerative medicine, and human cell therapy development. While there are several commercially available immunodeficient mouse and rat models, biomedical researchers still face insurmountable challenges that cannot be resolved due to the inherent limitations of their small body size and short lifespan, which limit their utility in translational studies. These models include monogenic knockout lines, such as Il2rg, Rag1 or 2, and Prkdc, as well as multigenic knockout lines on a non-obesity diabetic background, for example the popular NSG and NRG mice. Our lab has established multiple genetically engineered lines of immunodeficient New Zealand White rabbits, using CRISPR/Cas9 technology, including knockout models of critical immune system genes, such as FOXN1, RAG2, and IL2RG. This talk will focus on the research and development needed to overcome obstacles in the housing and care for immunodeficient rabbit models as well as the characterization of the NZRG rabbit, a new multigenic ultra-immunodeficient rabbit model.
Bio:
Dr. Pallas is a veterinary scientist and clinical associate professor of laboratory animal medicine at the University of Michigan. His expertise lies in the development and use of genetically modified rabbit models for biomedical research. His research efforts are focused on the creation and characterization of genetically engineered lines of immunodeficient rabbits, to provide the research community with a transformational non-rodent model for cancer research and regenerative medicine applications. He also serves as the Veterinary Director for the NIH funded National Center of Rabbit Models for Translational Research (NCRM). In these roles, he leads in-vivo experimental studies and provides guidance and oversight in the clinical, surgical, and pathological related aspects of newly generated disease models.
Abstract:
Immunodeficient rodent models have become essential to the advancement of many prominent biomedical fields, including immuno-oncology, regenerative medicine, and human cell therapy development. While there are several commercially available immunodeficient mouse and rat models, biomedical researchers still face insurmountable challenges that cannot be resolved due to the inherent limitations of their small body size and short lifespan, which limit their utility in translational studies. These models include monogenic knockout lines, such as Il2rg, Rag1 or 2, and Prkdc, as well as multigenic knockout lines on a non-obesity diabetic background, for example the popular NSG and NRG mice. Our lab has established multiple genetically engineered lines of immunodeficient New Zealand White rabbits, using CRISPR/Cas9 technology, including knockout models of critical immune system genes, such as FOXN1, RAG2, and IL2RG. This talk will focus on the research and development needed to overcome obstacles in the housing and care for immunodeficient rabbit models as well as the characterization of the NZRG rabbit, a new multigenic ultra-immunodeficient rabbit model.
Bio:
Dr. Pallas is a veterinary scientist and clinical associate professor of laboratory animal medicine at the University of Michigan. His expertise lies in the development and use of genetically modified rabbit models for biomedical research. His research efforts are focused on the creation and characterization of genetically engineered lines of immunodeficient rabbits, to provide the research community with a transformational non-rodent model for cancer research and regenerative medicine applications. He also serves as the Veterinary Director for the NIH funded National Center of Rabbit Models for Translational Research (NCRM). In these roles, he leads in-vivo experimental studies and provides guidance and oversight in the clinical, surgical, and pathological related aspects of newly generated disease models.
Related Links
Explore Similar Events
-
Loading Similar Events...
